JP2022548688A5 - - Google Patents
Info
- Publication number
- JP2022548688A5 JP2022548688A5 JP2022517369A JP2022517369A JP2022548688A5 JP 2022548688 A5 JP2022548688 A5 JP 2022548688A5 JP 2022517369 A JP2022517369 A JP 2022517369A JP 2022517369 A JP2022517369 A JP 2022517369A JP 2022548688 A5 JP2022548688 A5 JP 2022548688A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- disease
- hydroxypropyl methylcellulose
- bms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025124835A JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Tyk2阻害薬の徐放性剤形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902218P | 2019-09-18 | 2019-09-18 | |
| US62/902,218 | 2019-09-18 | ||
| PCT/US2020/051341 WO2021055651A1 (en) | 2019-09-18 | 2020-09-18 | Extended release dosage forms for tyk2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025124835A Division JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Tyk2阻害薬の徐放性剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548688A JP2022548688A (ja) | 2022-11-21 |
| JP2022548688A5 true JP2022548688A5 (cg-RX-API-DMAC10.html) | 2023-09-27 |
| JP7719770B2 JP7719770B2 (ja) | 2025-08-06 |
Family
ID=72670853
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517369A Active JP7719770B2 (ja) | 2019-09-18 | 2020-09-18 | Tyk2阻害薬の徐放性剤形 |
| JP2022517368A Active JP7812785B2 (ja) | 2019-09-18 | 2020-09-18 | Tyk2阻害薬の剤形 |
| JP2025124835A Pending JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Tyk2阻害薬の徐放性剤形 |
| JP2026012729A Pending JP2026090315A (ja) | 2019-09-18 | 2026-01-29 | Tyk2阻害薬の剤形 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517368A Active JP7812785B2 (ja) | 2019-09-18 | 2020-09-18 | Tyk2阻害薬の剤形 |
| JP2025124835A Pending JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Tyk2阻害薬の徐放性剤形 |
| JP2026012729A Pending JP2026090315A (ja) | 2019-09-18 | 2026-01-29 | Tyk2阻害薬の剤形 |
Country Status (21)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291452B1 (en) * | 2019-09-18 | 2026-06-01 | Bristol Myers Squibb Co | Dosage forms for TYK2 inhibitors |
| US20240325388A1 (en) * | 2020-09-18 | 2024-10-03 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| KR20240065283A (ko) | 2021-09-23 | 2024-05-14 | 브리스톨-마이어스 스큅 컴퍼니 | Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| JP2024539703A (ja) * | 2021-10-28 | 2024-10-29 | ブリストル-マイヤーズ スクイブ カンパニー | デュークラバシチニブの局所製剤 |
| WO2023181075A1 (en) * | 2022-03-24 | 2023-09-28 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof |
| AR128868A1 (es) * | 2022-03-25 | 2024-06-19 | Nimbus Lakshmi Inc | Formulaciones de inhibidor de tyk2 y métodos para elaborarlas |
| WO2024176263A1 (en) * | 2023-02-22 | 2024-08-29 | Cipla Limited | Deucravacitinib amorphous solid dispersions and polymorphs thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| ATE433318T1 (de) | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| ES2310164T3 (es) | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
| DK1242055T3 (da) | 1999-12-23 | 2008-07-21 | Pfizer Prod Inc | Hydrogelstyret doseringsform til lægemidler |
| MXPA03011784A (es) | 2001-06-22 | 2004-04-02 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros. |
| BR0307332A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
| WO2008084698A1 (ja) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | タクロリムス徐放性医薬組成物 |
| CN101152158B (zh) | 2007-08-21 | 2010-05-26 | 浙江大学 | 一种药物的双层芯渗透泵片的制备方法 |
| SMT202000093T1 (it) | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| US9095585B2 (en) | 2011-07-21 | 2015-08-04 | Bristol-Myers Squibb Company | Bioavailable compositions of amorphous piperidinyl compounds |
| TWI673051B (zh) * | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | 恩雜魯它脈(enzalutamide)之調和物 |
| EP2895150A1 (en) | 2012-09-11 | 2015-07-22 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| WO2014068402A2 (en) | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| HRP20220766T1 (hr) * | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| JP6634368B2 (ja) | 2013-03-14 | 2020-01-22 | アムジエン・インコーポレーテツド | 複素環式化合物及びそれらの使用 |
| LT3601268T (lt) | 2017-03-30 | 2021-05-25 | Bristol-Myers Squibb Company | 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas |
| CN118994118A (zh) | 2018-05-31 | 2024-11-22 | 百时美施贵宝公司 | 化合物的结晶形式 |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| IL291452B1 (en) * | 2019-09-18 | 2026-06-01 | Bristol Myers Squibb Co | Dosage forms for TYK2 inhibitors |
| US20240325388A1 (en) * | 2020-09-18 | 2024-10-03 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
-
2020
- 2020-09-17 IL IL291452A patent/IL291452B1/en unknown
- 2020-09-17 IL IL328425A patent/IL328425A/en unknown
- 2020-09-18 WO PCT/US2020/051342 patent/WO2021055652A1/en not_active Ceased
- 2020-09-18 SI SI202030709T patent/SI4031110T1/sl unknown
- 2020-09-18 AU AU2020349524A patent/AU2020349524B2/en active Active
- 2020-09-18 ES ES20781719T patent/ES3060149T3/es active Active
- 2020-09-18 SM SM20260127T patent/SMT202600127T1/it unknown
- 2020-09-18 HR HRP20260058TT patent/HRP20260058T1/hr unknown
- 2020-09-18 JP JP2022517369A patent/JP7719770B2/ja active Active
- 2020-09-18 EP EP20781719.8A patent/EP4031110B1/en active Active
- 2020-09-18 EP EP25216739.0A patent/EP4706778A3/en active Pending
- 2020-09-18 ES ES20781718T patent/ES3065958T3/es active Active
- 2020-09-18 MX MX2022003146A patent/MX2022003146A/es unknown
- 2020-09-18 LT LTEPPCT/US2020/051342T patent/LT4031110T/lt unknown
- 2020-09-18 CA CA3151369A patent/CA3151369A1/en active Pending
- 2020-09-18 CN CN202411436266.0A patent/CN119424434A/zh active Pending
- 2020-09-18 KR KR1020227012287A patent/KR20220066105A/ko active Pending
- 2020-09-18 CA CA3151137A patent/CA3151137A1/en active Pending
- 2020-09-18 FI FIEP20781719.8T patent/FI4031110T3/fi active
- 2020-09-18 US US17/639,481 patent/US12521390B2/en active Active
- 2020-09-18 AU AU2020348783A patent/AU2020348783B2/en active Active
- 2020-09-18 JP JP2022517368A patent/JP7812785B2/ja active Active
- 2020-09-18 PT PT207817198T patent/PT4031110T/pt unknown
- 2020-09-18 CN CN202411443114.3A patent/CN119424435A/zh active Pending
- 2020-09-18 WO PCT/US2020/051341 patent/WO2021055651A1/en not_active Ceased
- 2020-09-18 PL PL20781719.8T patent/PL4031110T3/pl unknown
- 2020-09-18 CN CN202411662444.1A patent/CN119700772A/zh active Pending
- 2020-09-18 CN CN202411670975.5A patent/CN119700773A/zh active Pending
- 2020-09-18 CN CN202411436265.6A patent/CN119424433A/zh active Pending
- 2020-09-18 BR BR112022004216A patent/BR112022004216A2/pt unknown
- 2020-09-18 US US17/639,489 patent/US20230255964A1/en active Pending
- 2020-09-18 CN CN202080078646.5A patent/CN114727949A/zh not_active Withdrawn
- 2020-09-18 RS RS20260116A patent/RS67803B1/sr unknown
- 2020-09-18 KR KR1020227012286A patent/KR20220066310A/ko active Pending
- 2020-09-18 BR BR112022004550A patent/BR112022004550A2/pt unknown
- 2020-09-18 DK DK20781719.8T patent/DK4031110T3/da active
- 2020-09-18 CN CN202411691316.XA patent/CN119745885A/zh active Pending
- 2020-09-18 EP EP20781718.0A patent/EP4031109B1/en active Active
- 2020-09-18 CN CN202080078644.6A patent/CN114727948A/zh not_active Withdrawn
- 2020-09-18 MX MX2022003150A patent/MX2022003150A/es unknown
-
2022
- 2022-03-15 MX MX2025014308A patent/MX2025014308A/es unknown
- 2022-03-15 MX MX2025014307A patent/MX2025014307A/es unknown
- 2022-03-16 IL IL291453A patent/IL291453A/en unknown
-
2025
- 2025-07-25 JP JP2025124835A patent/JP2025163082A/ja active Pending
- 2025-12-02 US US19/406,929 patent/US20260083734A1/en active Pending
- 2025-12-02 US US19/406,921 patent/US20260083733A1/en active Pending
-
2026
- 2026-01-29 JP JP2026012729A patent/JP2026090315A/ja active Pending